Read one actual disclosure before using it
Scroll sideways to compare all columns. Select a heading to sort.
| Incyte Corporation | INCY | COM | $3,487,217,729 | 30,762,330 | SH | None |
No matching rows. Clear the filter to see all records.
First displayed source row from Disclosed positions. The full bounded history and coverage notes remain below.
The displayed observation date is 2026-06-30 and its public availability date is 2026-08-15. Subtracting those calendar dates gives 46 days of disclosure lag. Historical public research can use the record from the availability date, rather than backdating knowledge to the observation date. The calendar-day difference does not assert an intraday publication time.
Read the amount together with its Unit and Option columns. A reported put or call position is not an option premium paid, and a quarterly holding is not a purchase made on its public filing date. Check every accession in the effective amendment lineage below: a retained holding can originate in an earlier filing rather than the latest linked amendment.
Open the linked original receipts to verify the row, then inspect a second record before drawing a pattern. This public filing observation supplies source evidence, not a completed copy-trading return.
Disclosed positions
Inspect all 50 displayed rows: Disclosed positions
Scroll sideways to compare all columns. Select a heading to sort.
| Incyte Corporation | INCY | COM | $3,487,217,729 | 30,762,330 | SH | None |
| BeOne Medicines Ltd. | ONC | SPONSORED ADS | $2,508,182,548 | 8,801,567 | SH | None |
| Revolution Medicines, Inc. | RVMD | COM | $2,143,111,899 | 11,443,357 | SH | None |
| Madrigal Pharmaceuticals, Inc. | MDGL | COM | $1,150,754,190 | 2,143,131 | SH | None |
| ACADIA Pharmaceuticals Inc. | ACAD | COM | $1,085,696,471 | 42,912,904 | SH | None |
| Kymera Therapeutics, Inc. | KYMR | COM | $992,725,940 | 8,657,242 | SH | None |
| Insmed Incorporated | INSM | COM PAR $.01 | $937,841,355 | 8,796,111 | SH | None |
| Celcuity Inc. | CELC | COM | $828,150,159 | 7,915,792 | SH | None |
| Kodiak Sciences Inc. | KOD | COM | $776,051,487 | 19,919,186 | SH | None |
| Rhythm Pharmaceuticals, Inc. | RYTM | COM | $622,265,747 | 5,604,483 | SH | None |
| Praxis Precision Medicines, Inc. | PRAX | COM | $586,953,158 | 1,753,198 | SH | None |
| Alkermes plc | ALKS | SHS | $524,592,729 | 10,012,267 | SH | None |
| Summit Therapeutics Inc. | SMMT | COM | $477,697,090 | 32,786,348 | SH | None |
| GRAIL, Inc. | GRAL | COM | $275,033,478 | 4,028,614 | SH | None |
| AbCellera Biologics Inc. | ABCL | COM | $259,145,283 | 33,012,138 | SH | None |
| Immunovant, Inc. | IMVT | COM | $209,419,027 | 5,435,220 | SH | None |
| IDEAYA Biosciences, Inc. | IDYA | COM | $186,723,818 | 5,010,030 | SH | None |
| Kiniksa Pharmaceuticals International, plc | KNSA | ORD SHS CL A | $181,275,420 | 2,834,643 | SH | None |
| Roivant Sciences Ltd. | ROIV | SHS | $166,928,649 | 4,716,831 | SH | None |
| Arrowhead Pharmaceuticals, Inc. | ARWR | COM | $162,431,742 | 1,992,783 | SH | None |
| Ionis Pharmaceuticals, Inc. | IONS | COM | $162,364,274 | 2,047,727 | SH | None |
| Edgewise Therapeutics, Inc. | EWTX | COM | $150,400,843 | 3,701,719 | SH | None |
| Replimune Group, Inc. | REPL | COM | $122,271,870 | 11,045,336 | SH | None |
| Nurix Therapeutics, Inc. | NRIX | COM | $113,016,569 | 4,658,556 | SH | None |
| Stoke Therapeutics, Inc. | STOK | COM | $109,176,726 | 3,336,697 | SH | None |
| Monte Rosa Therapeutics, Inc. | GLUE | COM | $105,166,811 | 4,345,736 | SH | None |
| Immatics N.V. | IMTX | SHS | $96,321,763 | 9,508,565 | SH | None |
| Denali Therapeutics Inc. | DNLI | COM | $96,047,122 | 3,734,336 | SH | None |
| Crinetics Pharmaceuticals, Inc. | CRNX | COM | $87,991,820 | 2,351,465 | SH | None |
| Dianthus Therapeutics, Inc. | DNTH | COM | $83,068,947 | 852,164 | SH | None |
| Structure Therapeutics Inc. | GPCR | SPONSORED ADS | $76,883,831 | 1,432,529 | SH | None |
| Celcuity Inc. | CELC | Note 2.75% 8/1/2031 | $69,158,687 | 30,750,000 | PRN | None |
| Rapport Therapeutics, Inc. | RAPP | COM | $64,467,240 | 1,547,090 | SH | None |
| Alumis Inc. | ALMS | COM | $56,631,750 | 2,012,500 | SH | None |
| Prelude Therapeutics Inc. | PRLD | COM | $53,959,982 | 10,123,824 | SH | None |
| Relay Therapeutics, Inc. | RLAY | COM | $52,889,110 | 2,826,783 | SH | None |
| Mirum Pharmaceuticals, Inc. | MIRM | COM | $52,210,293 | 445,975 | SH | None |
| Bicycle Therapeutics plc | BCYC | SPONSORED ADS | $46,153,914 | 10,885,357 | SH | None |
| Enliven Therapeutics, Inc. | ELVN | COM | $45,938,443 | 905,191 | SH | None |
| Celldex Therapeutics, Inc. | CLDX | COM | $44,004,955 | 1,182,611 | SH | None |
| Viridian Therapeutics, Inc. | VRDN | COM | $43,776,169 | 2,383,025 | SH | None |
| Design Therapeutics, Inc. | DSGN | COM | $38,756,882 | 2,678,430 | SH | None |
| Entrada Therapeutics, Inc. | TRDA | COM | $37,335,293 | 5,072,730 | SH | None |
| Faeth Therapeutics, Inc. | FTH | COM | $32,160,275 | 1,286,411 | SH | None |
| Aktis Oncology, Inc. | AKTS | COM | $32,112,393 | 996,351 | SH | None |
| Neurogene Inc. | NGNE | COM | $31,188,682 | 991,691 | SH | None |
| Jade Biosciences, Inc. | JBIO | COM | $27,340,066 | 1,230,426 | SH | None |
| Taysha Gene Therapies, Inc. | TSHA | COM SHS | $27,272,388 | 4,004,756 | SH | None |
| Arcus Biosciences, Inc. | RCUS | COM | $26,045,677 | 844,816 | SH | None |
| Disc Medicine, Inc. | IRON | COM | $25,573,913 | 349,657 | SH | None |
No matching rows. Clear the filter to see all records.
Largest 50 positions by reported value; the filing may contain more positions.
How amendments affect these holdings
This view uses 1 effective filing version(s). A restatement replaces the previous book; a new-holdings amendment adds positions. 2 positions lack a resolved ticker and 0 positions are put or call entries.
The displayed holdings combine the effective filing versions listed here. The latest receipt linked below identifies the current projection version; it is not proof that every retained holding originated in that latest amendment. Inspect all effective accessions when verifying a position's source.
A 13F is a delayed quarterly snapshot of disclosed holdings. It is not a complete trade ledger and does not reveal every position in a manager's portfolio. Option values refer to the reported underlying position rather than a traded option premium.
| Effective SEC accession | Role in this view |
|---|---|
| 0001104659-26-097191 | Latest effective version |
No matching rows. Clear the filter to see all records.
Quarter end and public filing date
Use the filing's public availability date when constructing a historical observation. The quarter-end report period is earlier and cannot be substituted for when the public learned the holdings.